Literature DB >> 31738828

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.

Sarah A Lau-Braunhut1, Hannah Stone1, Griffin Collins1, Sigbjørn Berentsen2, Benjamin S Braun1, Matt S Zinter1.   

Abstract

Entities:  

Year:  2019        PMID： 31738828      PMCID： PMC6880888          DOI： 10.1182/bloodadvances.2019000897

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  Failure of eculizumab to correct paroxysmal cold hemoglobinuria.

Authors:  Gareth Peter Gregory; Stephen Opat; Hang Quach; Jake Shortt; Huyen Tran
Journal:  Ann Hematol       Date:  2010-11-26       Impact factor: 3.673

Review 2.  Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Serena Marotta
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

Review 3.  Paroxysmal cold hemoglobinuria.

Authors:  Satish Shanbhag; Jerry Spivak
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

4.  Recurrent Donath-Landsteiner hemolytic anemia: a pediatric case report.

Authors:  Sara D Prince; Lena E Winestone; Sandra J Nance; David F Friedman
Journal:  Transfusion       Date:  2017-03-31       Impact factor: 3.157

5.  Erythropoiesis: Paroxysmal Cold Haemoglobinuria: A Clinico-Pathological Study of Patients with a Positive Donath-Landsteiner Test.

Authors:  R. J. Sokol; D. J. Booker; R. Stamps
Journal:  Hematology       Date:  1999       Impact factor: 2.269

Review 6.  Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.

Authors:  Antonio M Risitano
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

Review 7.  Two case studies and a review of paroxysmal cold hemoglobinuria.

Authors:  Stephanie N Slemp; Suzanne M Davisson; Jayanna Slayten; Douglas A Cipkala; Dan A Waxman
Journal:  Lab Med       Date:  2014

8.  Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Authors:  Alexander Röth; Martin Bommer; Andreas Hüttmann; Dörte Herich-Terhürne; Nils Kuklik; Jan Rekowski; Veronika Lenz; Hubert Schrezenmeier; Ulrich Dührsen
Journal:  Blood Adv       Date:  2018-10-09

9.  Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency.

Authors:  C L Conley; S M Lippman; P Ness
Journal:  JAMA       Date:  1980-10-10       Impact factor: 56.272

Review 10.  Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Authors:  Kioa Lente Wijnsma; Rob Ter Heine; Dirk Jan A R Moes; Saskia Langemeijer; Saskia E M Schols; Elena B Volokhina; Lambertus P van den Heuvel; Jack F M Wetzels; Nicole C A J van de Kar; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447
View more
  4 in total

Review 1.  Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.

Authors:  Morie A Gertz
Journal:  Hematol Oncol Clin North Am       Date:  2022-03-11       Impact factor: 2.861

2.  How to use Donath-Landsteiner test to diagnose paroxysmal cold haemoglobinuria (PCH).

Authors:  Jennifer Delun Williams; Ram K Jayaprakash; Heena Kithany; Mark Peter Tighe
Journal:  Arch Dis Child Educ Pract Ed       Date:  2021-08-25       Impact factor: 1.167

3.  A Case of Childhood Severe Paroxysmal Cold Hemoglobinuria with Acute Renal Failure Successfully Treated with Plasma Exchange and Eculizumab.

Authors:  Jessica Pelletier; Chad Ward; Matthew Borloz; Anne Ickes; Susan Guelich; Erwood Edwards
Journal:  Case Rep Pediatr       Date:  2022-04-22

Review 4.  Halting targeted and collateral damage to red blood cells by the complement system.

Authors:  M Jalink; E C W de Boer; D Evers; M Q Havinga; J M I Vos; S Zeerleder; M de Haas; I Jongerius
Journal:  Semin Immunopathol       Date:  2021-06-30       Impact factor: 9.623
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.